SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001723128-24-000018
Filing Date
2024-05-03
Accepted
2024-05-03 06:14:36
Documents
15
Period of Report
2024-05-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K amrx-20240503.htm   iXBRL 8-K 29507
2 EX-99.1 amrx-q12024ex991.htm EX-99.1 322445
6 amneala.jpg GRAPHIC 2670
  Complete submission text file 0001723128-24-000018.txt   508223

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT amrx-20240503.xsd EX-101.SCH 1995
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT amrx-20240503_lab.xml EX-101.LAB 21885
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT amrx-20240503_pre.xml EX-101.PRE 12599
19 EXTRACTED XBRL INSTANCE DOCUMENT amrx-20240503_htm.xml XML 2729
Mailing Address 400 CROSSING BOULEVARD 3RD FLOOR BRIDGEWATER NJ 08807
Business Address (908) 947-3120
Amneal Pharmaceuticals, Inc. (Filer) CIK: 0001723128 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38485 | Film No.: 24910686
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)